Prescription and funding: pressure redistribution mattress

In this phase, the trained health professional supports the person with spinal cord injury (SCI) to finalise selection of a pressure redistribution mattress.

This includes confirming the most appropriate option based on assessment and trial outcomes, and preparing clear clinical justification for funding approval.

Prescription

The trained health professional finalises the prescription. This defines the selected mattress, including all required features and accessories.

Prescription is informed by input from the person with SCI, their support network and the equipment provider, particularly for complex assistive technology (AT).

Considerations for prescription​

• prescription is completed collaboratively where possible, with access to the trial mattress and input from the equipment provider to support accurate configuration
• measurement requirements vary between mattress types and manufacturers. Accurate measurement supports appropriate fit, positioning and performance
• prescription processes may include manufacturer-specific documentation, which is completed in collaboration with the equipment provider and retained for records
• service provision considers the person’s location, ensuring access to delivery, setup, maintenance and repairs

Funding submission

The funding submission presents the clinical rationale for the selected mattress. It includes evidence from assessment and trial to support decision-making.

The submission supports understanding by funding bodies, including those without a clinical background, by clearly outlining the person’s needs and the role of the assistive technology.

Specific considerations for funding submission of ​pressure redistribution mattresses​ 

• eligibility and submission requirements for the relevant funding source are identified
• evidence from assessment and trial is included, such as clinical observations, trial outcomes and mattress specifications
• relevant multimedia recordings may be included where appropriate (for example photos or videos of positioning, transfers or trial outcomes) to support understanding of clinical need and complexity
• outcome measures and evaluation data are included where used, such as comfort, function, sleep quality and interface pressure mapping
• clinical justification clearly describes the purpose of each feature or accessory included in the quote
• the mattress is described in relation to the person’s environment, including compatibility with the bed and other equipment
• functional benefits are outlined, including support for bed mobility, transfers, daily activities and care tasks
• support requirements are described, including access for the support network and implications for care delivery
• safety considerations are addressed, including transfer safety, positioning and risk of skin breakdown
• integration with other assistive technology is described, such as bed systems, hoists or mobility equipment
• training and skill development needs are identified to support safe and effective use following delivery
• maintenance and servicing requirements are outlined, including anticipated costs where relevant
• risk management strategies are described, including prevention of skin breakdown, spasm management, respiratory support through positioning, and emergency considerations
• expected changes over time are considered, including ageing, changes in condition and history of skin breakdown
• impact on care needs and supports is described, including potential reduction in assistance requirements or improved efficiency of care
• all costs are included, such as equipment, accessories, freight, delivery and setup
• additional funding sources are identified where full costs are not covered by a single provider
• confirmation is provided that the selected mattress meets safe working load requirements